Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Advanced understanding of neurodegenerative diseases achieved by Trophos

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today the conclusion of the pan-European MitoTarget Project, the EU funded orphan disease project, with submission of the final report to the EC.

31 Jul 2012

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has earned a development milestone payment from GlaxoSmithKline, totaling $3.2 million. The milestone payment is related to progress in the companies' collaboration on the use of VaxiRNA technology for the production of GSK influenza vaccine.

30 Jul 2012

Protein associated with Huntington’s and other neurodegenerative diseases has several brain-specific forms

A protein essential for metabolism and recently associated with neurodegenerative diseases also occurs in several brain-specific forms. This discovery emerged in the course of a research project funded by the Austrian Science Fund FWF, the findings of which have now been published in the journal Human Molecular Genetics.

23 Jul 2012

GUMC, MedStar GUH launch Huntington Disease Care, Education and Research Center

Georgetown University Medical Center in collaboration with MedStar Georgetown University Hospital announce the launch of the Huntington Disease Care, Education and Research Center.

20 Jul 2012

New AAN guideline recommends several treatments for people with Huntington's chorea

A new guideline released by the American Academy of Neurology recommends several treatments for people with Huntington's disease who experience chorea—jerky, random, uncontrollable movements that can make everyday activities challenging.

19 Jul 2012

Statistical method uses evolutionary information to enhance identification of disease-associated alleles

A book containing misprints may cause annoyance for the reader, but typos in an individual's genetic blueprint (DNA) can mean serious disease or even death. The search for genetic correlates for the wide range of diseases plaguing humankind has inspired a wealth of research falling under the heading of genome-wide association studies (GWAS).

19 Jul 2012

Mitochondrial gene regulators involved in Huntington’s disease pathology

Researchers have identified two molecules involved in mitochondrial function that appear to be important in the pathogenesis of Huntington’s disease.

16 Jul 2012

Positive results from Alnylam’s ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the achievement of positive clinical results from its Phase I trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis.

16 Jul 2012

Five recent Science and Nature papers shed light on elusive 'GPCRs'

Readers of the top-ranked scientific journals Science and Nature might have noticed a recent wave of articles, most recently in the July 13, 2012 issue of Science, with deep importance for biology and medicine.

14 Jul 2012

New paper documents discovery of novel lipids, including MC3

Alnylam Pharmaceuticals, a leading RNAi therapeutics company, and collaborators announced today the publication of a scientific paper documenting the discovery of novel lipids used in second generation lipid nanoparticles (LNPs) for systemic delivery of RNAi therapeutics.

14 Jul 2012

PGC-1alpha and TFEB provide two new therapeutic targets for Huntington's disease

In a paper published in the July 11 online issue of Science Translational Medicine, researchers at the University of California, San Diego School of Medicine have identified two key regulatory proteins critical to clearing away misfolded proteins that accumulate and cause the progressive, deadly neurodegeneration of Huntington's disease.

12 Jul 2012

Oligodendroglia cells: An interview with Jeffrey Rothstein

There are three principle cells in the brain: neurons and two types of glial cells. One type is called an astrocyte. These were well known to inactivate neurotransmitters like glutamate, and provide metabolic support to neurons.

11 Jul 2012

Toxins and cell death: Interview with Professor Denise Montell

There are multiple kinds of cell death. Cells can undergo programmed cell death, which is a series of events that undergoes a predictable order at certain times during development.

6 Jul 2012

Study shows cells from different Parkinson’s patients have unique drug responses

Researchers have taken a step toward personalized medicine for Parkinson's disease, by investigating signs of the disease in patient-derived cells and testing how the cells respond to drug treatments.

5 Jul 2012

Potential link between mutant huntingtin, cell loss and cell death in Huntington's disease

Using an in vitro cell model of Huntington's disease (HD), researchers at Florida Atlantic University's Charles E. Schmidt College of Medicine have discovered a novel mechanism and potential link between mutant huntingtin, cell loss and cell death or apoptosis in the brain, which is responsible for the devastating effects of this disease. Apoptosis has been proposed as one of the mechanisms leading to neuronal death in HD.

2 Jul 2012

Scientists use patient cells to generate human model of Huntington's

Scientists at the Gladstone Institutes and an international team of researchers have generated a human model of Huntington's disease-directly from the skin cells of patients with the disease.

29 Jun 2012

New laboratory model for Huntington's disease

Cedars-Sinai scientists have joined with expert colleagues around the globe in using stem cells to develop a laboratory model for Huntington's disease, allowing researchers for the first time to test directly on human cells potential treatments for this fatal, inherited disorder.

29 Jun 2012

Researchers create 'Huntington's disease in a dish' to enable search for treatment

Johns Hopkins researchers, working with an international consortium, say they have generated stem cells from skin cells from a person with a severe, early-onset form of Huntington's disease (HD), and turned them into neurons that degenerate just like those affected by the fatal inherited disorder.

29 Jun 2012

New melatonin analogues more efficient in inhibiting NOS activity in Parkinson's disease

University of Granada researchers have tested melatonin analogues in rats as it inhibits the enzyme nitric oxide synthase (NOS), which is involved in the development of conditions as inflammatory bowel disease, septic shock or rheumatoid arthritis, as well as in neurodegenerative conditions as Huntington's disease, Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.

22 Jun 2012

Researchers can silence mutated gene responsible for Huntington's with single drug treatment

With a single drug treatment, researchers at the Ludwig Institute for Cancer Research at the University of California, San Diego School of Medicine can silence the mutated gene responsible for Huntington's disease, slowing and partially reversing progression of the fatal neurodegenerative disorder in animal models.

21 Jun 2012

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Advanced understanding of neurodegenerative diseases achieved by Trophos

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Protein associated with Huntington’s and other neurodegenerative diseases has several brain-specific forms

GUMC, MedStar GUH launch Huntington Disease Care, Education and Research Center

New AAN guideline recommends several treatments for people with Huntington's chorea

Statistical method uses evolutionary information to enhance identification of disease-associated alleles

Mitochondrial gene regulators involved in Huntington’s disease pathology

Positive results from Alnylam’s ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

Five recent Science and Nature papers shed light on elusive 'GPCRs'

New paper documents discovery of novel lipids, including MC3

PGC-1alpha and TFEB provide two new therapeutic targets for Huntington's disease

Oligodendroglia cells: An interview with Jeffrey Rothstein

Toxins and cell death: Interview with Professor Denise Montell

Study shows cells from different Parkinson’s patients have unique drug responses

Potential link between mutant huntingtin, cell loss and cell death in Huntington's disease

Scientists use patient cells to generate human model of Huntington's

New laboratory model for Huntington's disease

Researchers create 'Huntington's disease in a dish' to enable search for treatment

New melatonin analogues more efficient in inhibiting NOS activity in Parkinson's disease

Researchers can silence mutated gene responsible for Huntington's with single drug treatment

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in